SLAMF6 and neoplasm: To eliminate any systemic toxicity, glyco-modified NK cells were recently designed to specifically target the expression of NK-activation receptor (NKG2D) restricted on malignant cells, and the expression of E-selectin ligand to traffic to the bone-marrow-residing tumor cells expressing CD22 (Figure 5H) [248].